Literature DB >> 2413146

Cross-reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli J5 and other gram-negative bacteria.

G R Siber, S A Kania, H S Warren.   

Abstract

Antiserum to rough gram-negative mutants such as Escherichia coli J5 and Salmonella minnesota Re595 is thought to neutralize the toxic effects of lipopolysaccharides (LPSs). To verify that such antisera are capable of binding heterologous endotoxins, we examined IgG and IgM class antibodies induced in rabbits to a variety of LPSs. Immunization with rough mutants or lipid A induced high IgG antibody responses to the homologous purified LPS and relatively low but significant responses to heterologous LPSs. Increases in IgM antibodies were also primarily to homologous LPS. Immunization with smooth organisms induced little or no antibody to heterologous LPSs. Soluble LPS, outer membrane vesicles, and whole bacteria produced strong homologous inhibition but little or no heterologous inhibition in enzyme-linked immunosorbent assays. Cross-adsorption of antisera to rough mutants suggested that the IgG and IgM antibodies induced to heterologous LPS were adsorbed by the heterologous LPS and not by the core LPS used to immunize the animals. Rabbit antibody directed to J5 or Re595 LPS fails to bind to any substantial degree to heterologous LPS. Immunization with whole bacterial vaccines, particularly the rough mutants and lipid A, does increase antibody to a wide variety of antigens. The possibilities that the protective effects of antisera to rough mutants are due to a polyclonal antibody response or to the induction of as yet unidentified factor(s) deserve further investigation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413146     DOI: 10.1093/infdis/152.5.954

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum.

Authors:  J Hellman; P M Loiselle; M M Tehan; J E Allaire; L A Boyle; J T Kurnick; D M Andrews; K Sik Kim; H S Warren
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

Review 2.  Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.

Authors:  R Salomão; O Rigato; A C Pignatari; M A Freudenberg; C Galanos
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

3.  Passive immunization to outer membrane proteins MLP and PAL does not protect mice from sepsis.

Authors:  Catherine H Valentine; Judith Hellman; Laura K Beasley-Topliffe; Aranya Bagchi; H Shaw Warren
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

Review 4.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

5.  [Lipopolysaccharides, endotoxins and O-antigens of gram-negative bacteria: chemical structure, biologic effect and serologic properties].

Authors:  E T Rietschel; H Brade
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

6.  [Lipopolysaccharides, endotoxins and O-antigens of gram-negative bacteria: chemical structure, biologic effect and serologic properties].

Authors:  E T Rietschel; H Brade
Journal:  Infection       Date:  1987       Impact factor: 3.553

7.  A direct enzyme-linked immunosorbent assay (ELISA) for antibodies to enterobacterial Re core glycolipid and lipid A. Results in healthy subjects and in patients infected by gram-negative bacteria.

Authors:  M Nys; P Damas; F Damas; L Joassin; J Demonty
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

8.  Outer membrane vesicles derived from Salmonella Typhimurium mutants with truncated LPS induce cross-protective immune responses against infection of Salmonella enterica serovars in the mouse model.

Authors:  Qiong Liu; Qing Liu; Jie Yi; Kang Liang; Tian Liu; Kenneth L Roland; Yanlong Jiang; Qingke Kong
Journal:  Int J Med Microbiol       Date:  2016-08-25       Impact factor: 3.473

9.  Antibody specific for Escherichia coli J5 cross-reacts to various degrees with an Escherichia coli clinical isolate grown for different lengths of time.

Authors:  D E McCallus; N L Norcross
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

10.  Cross-reactivity of monoclonal antibodies and sera directed against lipid A and lipopolysaccharides.

Authors:  H M Kuhn
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.